Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index

Abstract

Background The neuropeptide substance P is a potential biomarker and therapeutic target in cancer. The main objectives of this study were to investigate the expression level of substance P in different breast cancer molecular subtypes and identify its association with clinicopathological parameters of patients and with Ki-67 index. Methods A retrospective analysis was performed for a total of 164 paraffin-embedded breast cancer tissue samples [42 Her2/neu-enriched, 40 luminal A, 42 luminal B (triple-positive) and 40 triple negative subtypes]. The tissue microarray slides containing specimens were used to determine the expression of substance p and Ki-67 by immunohistochemical staining. Results The mean age of the cohort was 51.35 years. Twenty two percent of cases had low substance P expression levels (TS ≤ 5), while 78% had high expression levels (TS > 5). A significant association was found between SP expression level and breast cancer molecular subtype (p = 0.002), TNM stage (p = 0.034), pN stage (p = 0.013), axillary lymph node metastasis (p = 0.004), ER and PR statuses (p<0.001) and history of DCIS (p = 0.009). The average percentage of Ki-67 expression was 27.05%. When analyzed as a continuous variable, significant differences were observed between the mean Ki-67 scores and molecular subtype (p = 0.001), grade (p = 0.003), pN stage (p = 0.007), axillary lymph node metastasis (p = 0.001), and ER and PR statuses (p <0.001). Conclusion SP is overexpressed in most of the analyzed tissues and has a negative prognostic value in the breast cancer patients. Besides substance P is a potential therapeutic target in breast cancer.

Aptamer-siRNA chimera and gold nanoparticle modified collagen membrane for the treatment of malignant pleural effusion

“…Ki-67 is the main marker of cell proliferation in clinicopathology ( Al-Keilani et al, 2021 ), while CD44 is an important marker of tumor invasion and metastasis ( Shinohara et al, 2016 ). Immunohistochemical results showed that ki-67 proliferation index and CD44 expression were significantly decreased in PD-1 inhibitor group, compared with the control group.…”

The Neurokinin-1 Receptor: A Promising Antitumor Target

“…Tumor size and lymph-node metastasis relate to the number of fibers containing SP [96][97][98]. In breast cancer, the overexpression of SP is associated with a negative prognostic value, the expression of NK-1R with a high Ki-67 index (the nuclear Ki-67 protein is related to proliferative mechanisms), and higher tumor grade [99,100]. The data suggest that NK-1R and SP may serve as predictive cancer factors.…”

Exploration of prognostic genes and risk signature in breast cancer patients based on RNA binding proteins associated with ferroptosis

“…Even though the prognosis for BRCA patients has significantly improved due to advancements in numerous treatment modalities such as local surgery, radiation, chemotherapy, and endocrine therapy, the risk of recurrence and death still exists for many individuals (Dong et al, 2018;Wang et al, 2020a). In clinical settings, the prognosis of BRCA patients is frequently predicted using the tumor size, tumor grade, and TNM Frontiers in Genetics frontiersin.org stage (Al-Keilani et al, 2021). However, because of individual variability, these clinical markers frequently fall short of the ideal prediction effect and the overall diagnostic standards.…”